Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 117 entries
View as:

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures

Phase: N/A Priority: Normal
NCT ID: NCT04519645 Org: User:
Start: 03/31/21 End: 10/31/24 Due: 10/31/25

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharamacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

Phase: N/A Priority: Normal
NCT ID: NCT05845645 Org: User:
Start: 05/31/23 End: 04/13/24 Due: 04/13/25

A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

Phase: N/A Priority: Normal
NCT ID: NCT05067335 Org: User:
Start: 10/21/21 End: 11/09/23 Due: 11/09/24

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT02718716 Org: User:
Start: 03/02/16 End: 02/04/19 Due: 02/04/20

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

Phase: N/A Priority: Normal
NCT ID: NCT04715646 Org: User:
Start: 03/11/21 End: 07/08/30 Due: 07/08/31

A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06511076 Org: User:
Start: 08/05/24 End: 11/26/24 Due: 11/26/25

A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04882540 Org: User:
Start: 05/19/21 End: 06/08/21 Due: 06/08/22

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

Phase: N/A Priority: Normal
NCT ID: NCT03728933 Org: User:
Start: 12/20/18 End: 07/25/22 Due: 07/25/23

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT04976322 Org: User:
Start: 07/27/21 End: 04/10/29 Due: 04/10/30

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT06617325 Org: User:
Start: 11/21/24 End: 09/15/27 Due: 09/15/28

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Phase: N/A Priority: Normal
NCT ID: NCT03928743 Org: User:
Start: 04/25/19 End: 08/08/22 Due: 08/08/23

Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT03532516 Org: User:
Start: - End: - Due: -

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT04009499 Org: User:
Start: 08/13/19 End: 05/25/26 Due: 05/25/27

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT06425549 Org: User:
Start: 06/25/24 End: 11/08/30 Due: 11/08/31

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT06149559 Org: User:
Start: 06/14/24 End: 08/17/26 Due: 08/17/27

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants

Phase: N/A Priority: Normal
NCT ID: NCT06312566 Org: User:
Start: 03/25/24 End: 06/04/24 Due: 06/04/25

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

Phase: N/A Priority: Normal
NCT ID: NCT05681715 Org: User:
Start: 04/17/23 End: 04/23/24 Due: 04/23/25

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Phase: N/A Priority: Normal
NCT ID: NCT06888193 Org: User:
Start: 07/31/25 End: 05/03/27 Due: 05/03/28

A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04123795 Org: User:
Start: 01/21/20 End: 08/15/34 Due: 08/15/35

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)

Phase: N/A Priority: Normal
NCT ID: NCT05063162 Org: User:
Start: 02/02/22 End: 07/01/27 Due: 07/01/28

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT04294667 Org: User:
Start: 08/12/20 End: 06/04/24 Due: 06/04/25

A Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on Padsevonil

Phase: N/A Priority: Normal
NCT ID: NCT04283136 Org: User:
Start: 02/24/20 End: 05/22/20 Due: 05/22/21

A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04705350 Org: User:
Start: 01/11/21 End: 07/28/21 Due: 07/28/22

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT06668181 Org: User:
Start: 03/11/25 End: 06/24/30 Due: 06/24/31

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT04225871 Org: User:
Start: 12/23/19 End: 06/02/26 Due: 06/02/27